PANG: Pangaea Oncology, S.A. - Summary | Jitta

Pangaea Oncology, S.A.

ESP:PANG

Notice
Stock data is incomplete.
Price
€1.54
Loss Chance
54.3%
2.19JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (47)
Recent Business Performance (56)
Financial Strength (32)
Return to Shareholders (4)
Competitive Advantage (35)
Jitta Signs
Revenue and EarningEarning loss detected in 2023
Operating MarginInconsistent
Recent Business PerformanceEarning decline 89.27% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
CapExVery High
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
2.19
100.00%
4.64
105.67%
COMPANY DESCRIPTION
Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. It offers molecular diagnostics, such as mutation analysis in tissue and liquid biopsy, gene amplification and translocation testing, immunohistochemistry and fluorescence in-situ hybridization, and gene expression profiling; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnostic platform validation. The company also provides biomarker discovery to improve treatment through identification of novel theranostic biomarkers. Pangaea Oncology, S.A. was incorporated in 2006 and is based in Barcelona, Spain.